McAdam LLC’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $661K | Buy |
27,456
+6,523
| +31% | +$171K | 0.03% | 227 |
|
|
2026
Q1 | $588K | Sell |
20,933
-1,853
| -8% | -$49.3K | 0.03% | 219 |
|
|
2025
Q4 | $567K | Buy |
22,786
+8,266
| +57% | +$208K | 0.03% | 213 |
|
|
2025
Q3 | $370K | Buy |
14,520
+846
| +6% | +$20.9K | 0.02% | 263 |
|
|
2025
Q2 | $331K | Buy |
13,674
+706
| +5% | +$16.5K | 0.02% | 268 |
|
|
2025
Q1 | $329K | Sell |
12,968
-7,667
| -37% | -$201K | 0.02% | 249 |
|
|
2024
Q4 | $547K | Sell |
20,635
-898
| -4% | -$24.4K | 0.03% | 193 |
|
|
2024
Q3 | $623K | Buy |
21,533
+2,628
| +14% | +$76.7K | 0.04% | 175 |
|
|
2024
Q2 | $529K | Buy |
18,905
+3,418
| +22% | +$94.1K | 0.03% | 174 |
|
|
2024
Q1 | $430K | Buy |
15,487
+468
| +3% | +$13K | 0.03% | 184 |
|
|
2023
Q4 | $432K | Buy |
15,019
+1,063
| +8% | +$32.1K | 0.03% | 174 |
|
|
2023
Q3 | $463K | Buy |
13,956
+1,031
| +8% | +$36.5K | 0.04% | 162 |
|
|
2023
Q2 | $474K | Buy |
12,925
+432
| +3% | +$16.8K | 0.04% | 157 |
|
|
2023
Q1 | $510K | Buy |
12,493
+3,666
| +42% | +$158K | 0.05% | 149 |
|
|
2022
Q4 | $521K | Sell |
8,827
-1,390
| -14% | -$66.6K | 0.05% | 101 |
|
|
2022
Q3 | $447K | Sell |
10,217
-61
| -0.6% | -$2.96K | 0.05% | 135 |
|
|
2022
Q2 | $539K | Buy |
10,278
+1,420
| +16% | +$72.4K | 0.06% | 128 |
|
|
2022
Q1 | $459K | Buy |
8,858
+31
| +0.4% | +$1.61K | 0.04% | 117 |
|
|
2021
Q4 | $521K | Buy |
8,827
+2,675
| +43% | +$133K | 0.05% | 101 |
|
|
2021
Q3 | $265K | Buy |
6,152
+114
| +2% | +$5.05K | 0.03% | 146 |
|
|
2021
Q2 | $258K | Buy |
+6,038
| New | +$235K | 0.03% | 147 |
|
|
2021
Q1 | – | Sell |
-6,350
| Closed | -$240K | – | 167 |
|
|
2020
Q4 | $240K | Sell |
6,350
-4,935
| -44% | -$181K | 0.04% | 141 |
|
|
2020
Q3 | $393K | Buy |
11,285
+2,175
| +24% | +$76.3K | 0.07% | 79 |
|
|
2020
Q2 | $283K | Buy |
9,110
+1,531
| +20% | +$52K | 0.06% | 92 |
|
|
2020
Q1 | $235K | Sell |
7,579
-2,673
| -26% | -$91.1K | 0.06% | 89 |
|
|
2019
Q4 | $381K | Buy |
10,252
+273
| +3% | +$9.72K | 0.09% | 53 |
|
|
2019
Q3 | $340K | Buy |
9,979
+2,787
| +39% | +$101K | 0.09% | 54 |
|
|
2019
Q2 | $296K | Buy |
7,192
+96
| +1% | +$3.81K | 0.09% | 56 |
|
|
2019
Q1 | $286K | Buy |
7,096
+725
| +11% | +$29K | 0.09% | 54 |
|
|
2018
Q4 | $264K | Sell |
6,371
-3,076
| -33% | -$128K | 0.1% | 53 |
|
|
2018
Q3 | $396K | Buy |
9,447
+4,527
| +92% | +$174K | 0.15% | 41 |
|
|
2018
Q2 | $169K | Buy |
4,920
+173
| +4% | +$5.91K | 0.07% | 65 |
|
|
2018
Q1 | $160K | Buy |
+4,747
| New | +$163K | 0.07% | 69 |
|
|
2017
Q1 | – | Sell |
-9,366
| Closed | -$289K | – | 49 |
|
|
2016
Q4 | $289K | Buy |
+9,366
| New | +$286K | 0.29% | 36 |
|
Other funds holding PFE
McAdam LLC's PFE Position: Q2 2026 in Review
McAdam LLC increased its Pfizer (PFE) stake by 31% in Q2 2026, buying an estimated $171K and bringing the position to 27,456 shares worth $661K. The position accounts for 0.03% of the portfolio, ranked #227.
McAdam LLC first reported a position in PFE in Q4 2016 and has held it in 34 quarters since. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- McAdam LLC held 27,456 shares of Pfizer worth $661K as of Q2 2026.
- McAdam LLC bought 6,523 Pfizer shares in Q2 2026, an estimated $171K.
- Pfizer made up 0.03% of McAdam LLC's portfolio in Q2 2026, its #227 holding.
- McAdam LLC first reported a position in Pfizer in Q4 2016 and has held it in 34 quarters since.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on McAdam LLC's 13F filing for Q2 2026, filed 4 Aug 2026.